{
    "organizations": [],
    "uuid": "283ad98f1837e3323d67090bb97f548fff738eaf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-syros-announces-clinical-supply-ag/brief-syros-announces-clinical-supply-agreement-with-janssen-to-evaluate-sy-1425-idUSASB0BZFC",
    "ord_in_thread": 0,
    "title": "BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 2, 2018 / 1:19 PM / in 9 minutes BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425 Reuters Staff 1 Min Read \nJan 2 (Reuters) - Syros Pharmaceuticals Inc: \n* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS \n* SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS’ ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 \n* SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT \n* SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T15:17:00.000+02:00",
    "crawled": "2018-01-02T15:36:35.024+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "announces",
        "clinical",
        "supply",
        "agreement",
        "janssen",
        "evaluate",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "syros",
        "pharmaceutical",
        "inc",
        "syros",
        "announces",
        "clinical",
        "supply",
        "agreement",
        "janssen",
        "evaluate",
        "selective",
        "rarα",
        "agonist",
        "combination",
        "daratumumab",
        "genomically",
        "defined",
        "aml",
        "md",
        "patient",
        "syros",
        "pharmaceutical",
        "janssen",
        "supply",
        "daratumumab",
        "combination",
        "dosing",
        "cohort",
        "syros",
        "ongoing",
        "phase",
        "clinical",
        "trial",
        "syros",
        "pharmaceutical",
        "janssen",
        "receive",
        "access",
        "data",
        "cohort",
        "evaluating",
        "safety",
        "efficacy",
        "combination",
        "daratumumab",
        "research",
        "development",
        "syros",
        "pharmaceutical",
        "begin",
        "enrolling",
        "patient",
        "combination",
        "cohort",
        "daratumumab",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}